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Abstract
Background:  Angiogenesis, a complex multistep process that comprehends proliferation,
migration and anastomosis of endothelial cells (EC), has a major role in the development of
pathologic conditions such as inflammatory diseases, tumor growth and metastasis. Brazilian flora,
the most diverse in the world, is an interesting spot to prospect for new chemical leads, being an
important source of new anticancer drugs. Plant-derived alkaloids have traditionally been of
interest due to their pronounced physiological activities. We investigated the anti-angiogenic
potential of the naturally occurring guanidine alkaloid pterogynidine (Pt) isolated from the Brazilian
plant  Alchornea glandulosa. The purpose of this study was to examine which features of the
angiogenic process could be disturbed by Pt.
Methods: Human umbilical vein endothelial cells (HUVEC) were incubated with 8 μM Pt and cell
viability, proliferation, apoptosis, invasion and capillary-like structures formation were addressed.
Nuclear factor κB (NFκB), a transcription factor implicated in these processes, was also evaluated
in HUVEC incubated with Pt. Quantifications were expressed as mean ± SD of five independent
experiments and one-way analysis of variance (ANOVA) followed by the Dunnet test was used.
Results: A significant decrease in proliferation and invasion capacity and an effective increase in
apoptosis as assessed by bromodeoxyuridine (BrdU), double-chamber and terminal transferase
dUTP nick end labeling (TUNEL) assay, respectively, have been found. Pt also led to a drastic
reduction in the number of capillary-like structures formation when HUVEC were cultured on
growth factor reduced-Matrigel (GFR-Matrigel) coated plates. In addition, incubation of HUVEC
with Pt resulted in reduced NFκB activity.
Conclusion: These findings emphasize the potential use of Pt against pathological situations where
angiogenesis is stimulated as tumor development.
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Background
Angiogenesis, the formation of new capillaries from pre-
existing vessels, plays a major role in several physiological
and pathological events. It is an important process during
pathologic conditions such as inflammatory diseases,
tumor growth and metastasis [1]. This complex multistep
process comprehends the extracellular matrix degrada-
tion, endothelial cells (EC) proliferation, migration and
anastomosis, ending up by the recruitment and adhesion
of pericytes or smooth muscle cells [2].
In tumor pathogenesis, angiogenesis is crucial and it sus-
tains malignant cells with nutrients and oxygen. Tumor
cells secrete various growth factors which triggers EC to
form new capillaries. Preventing the expansion of new
blood vessel networks results in reduced tumor size and
metastases [3]. Since angiogenesis is essential for tumor
development and tumor vasculature is considered an
optimal target for anti-cancer strategies, many researchers
are testing compounds of different origin and mechanism
of action trying to develop antiangiogenic agents as a
treatment for malignancy or as an adjunct to standard
chemotherapeutic regimens [4-7].
Throughout history, natural products have afforded a rich
source of compounds that have found many applications
in the fields of medicine, pharmacy and biology. Within
the sphere of cancer, a number of important new com-
mercialized drugs have been obtained from natural
sources, by structural modification of natural com-
pounds, or by the synthesis of new compounds, designed
following a natural compound as model [8].
The Brazilian flora, the most diverse in the world, is an
interesting spot to prospect for new chemical leads due to
its species diversity and associated chemical richness [9].
Therefore, plants from the Brazilian forests are important
sources of new anticancer drugs [9-11].
Among several types of compounds obtained from plants,
alkaloids have traditionally been of interest due to their
pronounced and various physiological activities in ani-
mals and humans [12]. The most famous examples of
anticancer alkaloids are taxol (clinically available since
1994) from the western yew, Taxus brevifolia, and camp-
tothecin and derivatives, currently in clinical trials, from
Camptotheca acuminata [13-15]. The alkaloid taspine
hydrochloride founded in Sangre de grado plant is also
considered a potential anticancer agent [16] and homo-
harringtonine, an alkaloid isolated from the Chinese tree
Cephalotaxus harringtonia (Cephalotaxacea), has shown
efficacy against various leukemias [17].
In the plant kingdom, guanidine alkaloids are restricted to
the families Euphorbiaceae and Leguminosae [18].
Alchornea glandulosa Poepp & Endl. (Euphorbiaceae) is a
plant distributed from southeast to south of Brazil,
mainly in the Atlantic pluvial Forest [19]. Popularly
known as Tapiá, it was found to exert anti-inflammatory
activity and have therapeutic potential in the control of
inflammatory disorders [20].
Pterogynidine (Pt) (Figure 1), a naturally occurring guani-
dine alkaloid, was isolated from the leaves of A. glandu-
losa. In a previous report, Bolzani et al. [18] tested the
cytotoxic activity of Pt in genetically engineered strains of
the yeast Saccharomyces cerevisiae for mechanism-based
anticancer activity. This alkaloid was found to be active in
the mutant strain RS 321, suggesting its potential as anti-
tumoral agent.
However, the potential effect of Pt on angiogenesis had
not yet been studied. The aim of the current research was
to identify the effects of Pt within the angiogenic process.
Accordingly, the present study addressed cell viability,
proliferation, apoptosis, invasion and capillary-like struc-
tures formation in EC cultures. Moreover, knowing that
NFκB signaling pathway is involved in all these cell proc-
esses, we investigated if the mechanism of Pt antiang-




Leaves of Alchornea glandulosa Poepp & Endl. (Euphor-
biaceae) were collected in the Biological Reserve and
Pterogynidine (Pt) Figure 1
Pterogynidine (Pt). Molecular structure of the guanidine 
alkaloid pterogynidine.BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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Experimental Station at Mogi Guaçu, São Paulo State, Bra-
zil, in March 2005, and a voucher specimen (SP319257)
has been deposited in the herbarium of the Botanic Insti-
tute (São Paulo-SP, Brazil). The shade-dried leaves (1.5
kg) were ground and defatted with n-hexane (3.5 L × 3, at
room temperature) and exhaustively extracted by macera-
tion with methanol (4.2 L × 3). The methanol extract was
concentrated under reduced pressure to yield 3.8 g of a
syrup residue. The concentrate was then diluted with
methanol:water (4:1) and successively partitioned with
ethyl acetate and n-butanol. After solvent removal using
rotaevaporator, each partition phase yield 2.5 g and 0.8 g,
respectively. The ethyl acetate residue (2.0 g) was chroma-
tographed by gel permeation over Sephadex LH-20 (Phar-
macia®) eluted with methanol to afford eleven fractions
(A1-A11). Chromatographic purification of fraction A3
(330 mg) by RP-HPLC [acetonitrile:water:acetic acid
(87:12.5:0.5), UV detection at 237 nm; flow rate 12 mL/
min] led to the isolation of Pt (183 mg). The identifica-
tion was based on analysis of 1H, 13C NMR and MS data,
as well as by comparison with authentic material available
in our laboratory [18].
Culture of Human Umbilical Vein Endothelial Cells 
(HUVEC)
Human umbilical vein endothelial cells (HUVEC) were
obtained from ScienceCell Research Labs (San Diego,
USA), is a primary endothelial cell culture most com-
monly used for angiogenic assays. Cells were used
between passages 5 and 15. HUVEC cultures were first
established in M199 medium (Sigma-Aldrich, Portugal)
supplemented with 20% fetal bovine serum (FBS) (Invit-
rogen Life Technologies, Scotland, UK), 1% penicillin/
streptomycin (Invitrogen Life Technologies, Scotland,
UK), 0.01% heparin (Sigma-Aldrich Portugal) and 30 μg/
ml endothelial cell growth supplement (ECGS) (Sigma-
Aldrich, Portugal), and maintained at 37°C in a humidi-
fied 5% CO2 atmosphere. Cells were seeded on plates
coated with 0.2% gelatin (Sigma) and allowed to grow.
Cell media were changed every other day.
Preparation of Pt samples
Pterogynidine (Pt) was dissolved in dimethyl sulfoxide
(DMSO) and added to cell culture M199 medium at a
concentration range of 8 μM to 128 μM for MTT assay pur-
poses. The concentration of 8 μM was established for the
following experiments according to MTT findings. Every
experiment was carried out by adding Pt to serum-free
M199 medium containing ECGS during 24 h as estab-
lished in previous assays (unpublished data). Control
cells were incubated with M199 medium and 0.1%
DMSO (vehicle). DMSO concentration was 0.1% in every
culture.
MTT Assay
HUVEC (5 × 104) were allowed to grow until 70–90%
confluence and then incubated with Pt at a concentration
range of 8, 16, 32, 64 and 128 μM or 0.1% DMSO M199
medium (control) for 24 h. After the incubation period,
cells were washed twice with PBS and subjected to MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide] assay, as previously described [21]. The choice of
the indicated concentrations of Pt in the MTT assay was
based on previous research of our group (unpublished
data).
BrdU Proliferation Assay
HUVEC (5 × 104) were cultured following standard con-
ditions or the treatment procedures for 24 h. Cells were
then washed twice with PBS and subjected to in situ detec-
tion with BrdU (bromodeoxyuridine), an index of DNA
synthesis and cell proliferation. Cells were incubated with
BrdU solution at a final concentration of 0.01 mM for 24
h and then the in situ detection was performed using BrdU
In situ Detection Kit (BD Biosciences Pharmingen, USA),
according to the manufacturer's instructions. The results
are given as mean ± SD and expressed as percentage of
proliferating cells. The percentage of proliferating cells
was evaluated at a 200× magnification field. A total of
1,000 nuclei were evaluated. Five independent experi-
ments were performed.
Tunel Assay
Cells (2 × 104) plated in glass coverslips were grown for 24
h and then incubated with Pt or 0.1% DMSO M199
medium (control) for 24 h. TUNEL assay (Terminal deox-
ynucleotidyl transferase mediated deoxyuridine triphos-
phate nick-end labeling) was performed using the In Situ
Cell Death Detection kit (Roche Diagnostics, Basel, Swit-
zerland), according to the manufacturing instructions
[21,22]. Apoptosis was determined as the percentage of
positive cells per 1000 DAPI-stained nuclei. Glass cover-
slips were visualized under a fluorescence microscope
(Nikon Eclipse 50i) at a magnification of 200×.
Invasion Assay
The invasive cell behavior in the presence of Pt was quan-
tified in vitro using a double-chamber assay by counting
the number of cells that invaded Transwell BD-Matrigel
basement membrane matrix inserts (BD-Biosciences, Bel-
gium), according to manufacturer's instructions. FBS was
used as chemoattractant. Results represent the ratio
between invading cells in Pt treated cultures and in con-
trol cultures for the same initial amount of cells seeded.
Matrigel assay – Tube Formation Index
Matrigel assay was performed on growth factor reduced-
Matrigel (GFR-Matrigel) (BD Biosciences, Belgium)-
coated plates for 24 h as previously described [23]. Briefly,BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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cells (2 × 104) were cultured on GFR-Matrigel-coated
plates for 24 h, in medium containing 8 μM Pt or 0.1%
DMSO M199 medium (control). When cultured on
Matrigel, EC assemble into capillary-like structures. The
number of cord-like structures was then measured and
photomicrographs were also taken using an inverted
microscope (400× magnification). Each cord portion
between the ramifications was considered one cord unit.
Mean values were obtained by evaluating the whole cul-
tures of each well under the same treatment. A semi-quan-
titative measurement of cord formation in GFR-Matrigel
cultured HUVEC was developed (tube formation index)
as previously described [23].
NFκB activity
NFκB activity was determined by ELISA assay. As previ-
ously reported [24], unstimulated whole cell lysates were
obtained and quantified by BCA protein assay kit (Pierce,
USA). NFκB activity in cell lysates obtained from 8 μM Pt
or control (DMSO treated) HUVEC was measured using
TransAM NFκB p50 transcription factor assay kit (Active
Motif, CA, USA). In brief, protein samples (20 μg) were
added to a 96-well plate with immobilized oligonucle-
otide containing the NFκB consensus site. Sample wells
were incubated with NFκB p50 subunit primary antibody,
followed by incubation with HRP-conjugated secondary
antibody. Quantification was performed at 450 nm and
650 nm using a plate reader (Thermo Electron Corpora-
tion, Multiskan Ascent, USA).
Statistical Analysis
All experiments were performed in triplicate. Quantifica-
tions are defined as mean ± SD of five independent exper-
iments and expressed as percentage of control, which was
considered to be 100%. Statistical significance of differ-
ence between various groups was evaluated by one-way
analysis of variance (ANOVA test) followed by the Tukey-
Kramer multiple comparisons test. For comparison
between two groups, one-way analysis of variance
(ANOVA test) followed by the Dunnet test was used. A
difference between experimental groups was considered
statistically significant whenever the p value was < 0.05.
Results
Effects of Pt in HUVEC
To study whether Pt exerted any effect on EC, HUVEC
were incubated with five different Pt concentrations (8,
16, 32, 64 and 128 μM) and cell viability was assessed by
MTT test. Incubation with Pt resulted in decreased cell via-
bility in a dose-dependent manner as evaluated by MTT
assay. A reduction to 63% of control values was found
upon treatment with 8 μM Pt (63.33% ± 8.12%; *p < 0.01
vs. control) (Figure 2). In addition, cell viability of 8 μM
Pt was also significantly different from the three highest Pt
concentrations. Incubation of HUVEC with the highest
concentration of Pt (128 μM) effectively decreased cell
viability even when compared to 8 μM, 16 μM and 32 μM
Pt. These findings prompted us to use the 8 μM concentra-
tion of the alkaloid in the following experiments.
We observed a very significant decrease in the percentage
of proliferating cells (11.79% ± 4.02%; *p < 0.01 vs. con-
trol) (Figure 3) and a strong increase in the percentage of
apoptotic cells (1771.43% ± 122.81%; *p < 0.01 vs. con-
trol) (Figure 4a, Figure 4b) after incubation with 8 μM Pt
as evaluated by BrdU and TUNEL assay, respectively.
We next investigated whether Pt affected migration and
invasion capacity of HUVEC using a double-chamber
assay. As illustrated in Figure 5, Pt resulted in a very signif-
icant decrease in the migratory capacity of HUVEC
(4.09% ± 2.95%; *p < 0.01 vs. control).
Effects of Pt in cord-like structures formed by HUVEC
To form a new blood vessel, EC must assemble into vascu-
lar capillary structures. HUVEC are able to assemble into
highly branched capillary-like structures when cultured
on GFR-Matrigel. Therefore, we next examined whether Pt
was able to affect the formation of these structures. Incu-
bation of HUVEC with M199 medium and 0.1% DMSO
(control), during 24 h, led to the formation of highly ram-
ified cord-like structures. However, the presence of Pt led
to a drastic reduction in the number of these cord-like
structures into 0.2% ± 0.45% of control values (*p < 0.01
vs control).
Ramifications have pratically disappeared when HUVEC
were treated with Pt in comparison to controls and just
undifferentiated round-shaped cells could be seen under
the microscope. These findings indicate that Pt at a con-
centration as low as 8 μM was able to inhibit vessel assem-
bly, a crucial feature for the angiogenic process (Figure 6a
and 6b).
Pt inhibited NFκB activity in HUVEC
NFκB is a transcription factor involved in many cell fates,
including cell growth, apoptosis, migration and stimula-
tion of inflammatory factors [2,25]. The broad effects of 8
μM Pt in HUVEC prompted us to examine whether the
activity of this factor was affected by the alkaloid using
NFκB ELISA assay. A strong decrease in NFκB p50 subunit
activity (63.67% ± 9.51%; *p < 0.01 vs. control) was
found in HUVEC after incubation with Pt, indicating that
NFκB signaling inactivation is one of the pathways trig-
gered by Pt (Figure 7).
Discussion
Angiogenesis has been described as one of the hallmarks
of cancer, playing a fundamental role in tumor growth,
invasion, and metastasis. In many pathological condi-BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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tions, including chronic inflammation, diabetic retinopa-
thy, rheumatoid arthritis or atherosclerosis, persistent
upregulated angiogenesis is a common feature [26]. Thus,
the central importance of angiogenesis and the under-
standing of how new blood vessels are formed have led to
novel therapies designed to interrupt this process [27]. As
part of our search for natural product-based antiang-
iogenic agents, we studied the effects of the pterogynidine
alkaloid obtained from the Brazilian plant A. glandulosa in
the angiogenic course, namely investigating cell viability,
proliferation, migration, invasion and capillary-like struc-
ture formation using EC.
Natural products have been the most significant source of
drugs and drug leads. Their dominant role in cancer
chemotherapeutics is clear with about 74% of anticancer
compounds being either natural products or natural prod-
uct-derived [28]. Numerous bioactive chemical com-
pounds of plant origin may influence the angiogenic
activity of various cell types and may thus affect the for-
mation of blood vessels [29,30]. Nowadays, several alka-
loids are currently being exploited to target angiogenesis.
Sanguinarine, an alkaloid isolated from the root of San-
guinaria canadensis, and Vinca alkaloids, obtained from
Catharanthus roseus which are found in the rain forests of
Madagascar, appear to be antiangiogenic natural products
[31-34]. Moreover, halofuginone, an alkaloid from the
plant Dichroa febrifuga, is considered to be a potent inhib-
itor of critical steps in angiogenesis progression [35].
The first experimental strategy for the screening of new
anti-angiogenic compounds is the search of EC growth
inhibitors [26]. Additionally, apoptosis appears to be fun-
damental in the initiation of the anti-angiogenic process
[36]. In the current study, we demonstrated that Pt, a gua-
nidine alkaloid, possesses antiangiogenic activity in sev-
Effect of Pt in HUVEC viability evaluated by MTT assay Figure 2
Effect of Pt in HUVEC viability evaluated by MTT assay. After incubation with 8 μM Pt, the percentage of cell viability 
was 63.33% ± 8.12% as evaluated by MTT assay. Results are expressed as percentage of control cells. Bars represent mean ± 
SD. Assays were repeated five times and performed in triplicate. Statistical significance between various groups was evaluated 
by one-way analysis of variance (ANOVA test) followed by the Tukey-Kramer multiple comparisons test. *p < 0.001 vs. Con-
trol; black diamond: p < 0.01 of 8 μM vs. 32 μM; black spade: p < 0.01 of 8 μM vs. 64 μM; §p < 0.001 of 8 μM vs. 128 μM; #p < 
0.001 of 16 μM vs. 128 μM; black club: p < 0.05 of 32 μM vs. 128 μM.BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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eral  in vitro assays. Although cytotoxicity was only
evaluated by MTT in the current study, incubation with 8
μM Pt led to a reduction in the number of viable cells only
to 63% of control values (see MTT assay – Figure 2). More-
over, this decrease was significantly less than the ones
obtained after treatment with the other higher Pt concen-
trations analyzed. These findings, together with the fact
that 8 μM Pt was used in macrophage cultures in previous
studies of our group with no significant cytotoxicity
(unpublished data), prompt us to use the concentration
of 8 μM for Pt during the whole study. Incubation with 8
μM Pt resulted in a drastic reduction in the percentage of
EC proliferation and a strong increase of HUVEC apop-
totic cells as compared to controls (Figure 3, Figure 4a and
Figure 4b). Furthermore, 8 μM concentration of Pt was
enough to induce an 8-fold decrease in the percentage of
EC proliferation and a 17-fold increase in apoptotic rate as
compared to controls. These results were expected, since
antiproliferative and pro-apoptotic effects of other alka-
loids and plant extracts have already been described in
cancer cells [37,38], implying that a similar mechanism is
probably occurring in EC as well.
Another plant from the Alchornea genus also possesses
guanidine alkaloids.Alchornea cordifolia is one of the most
widely-used plants in traditional medicine throughout
Africa, mainly for its anti-inflammatory, antimicrobial
and antiparasitic properties [39]. Two guanidine alka-
loids, N1, N2-diisopentenyl guanidine and N1, N2, N3-
triisopentenyl guanidine, isolated from A. cordifolia root
bark, showed cytotoxic properties on cancer cells [40].
The alkaloids represent a very diverse group of medically
significant compounds. They were originally defined as
pharmacologically active, nitrogen-containing basic com-
pounds of plant origin. Alkaloids are not unique to plants.
They have also been isolated from numerous animal
sources [41]. Guanidine alkaloids are present in marine
organisms displaying various biological activities as cyto-
toxicity against tumor cell lines and inhibition of HIV-1
fusion [42-44].
EC invasive behaviour is another mainstay in angiogen-
esis. Invasive capacity requires extracellular matrix degra-
dation and involves the activation of many EC signalling
pathways. Our findings show a very effective decrease in
Matrigel invasion in Pt-treated HUVEC, Pt being about 25
times more potent than control to inhibit the migratory
capacity of HUVEC (Figure 5). Therefore, our findings
suggest that Pt significantly reduced EC invasion and indi-
cate the potential of this compound as an anti-angiogenic
agent. In agreement with our study, Quesada et al. [26]
pointed out that squalamine (Sq), a natural product iso-
lated from the shark Squalus acanthias, inhibits angiogen-
esis and tumor growth, at least in part, by blocking
mitogen-induced proliferation and migration of EC, thus
preventing neovascularization of the tumor. Sq has a huge
potential as a non-invasive anti-angiogenic therapy for
ocular disorders, being evaluated in aged-related macular
degeneration.
Finally, the anti-angiogenic activity of Pt was further dem-
onstrated by tube formation assay performed on growth
factor reduced-Matrigel. EC must assemble into capillary-
like structures, in order to form a new blood vessel. We
were able to show that Pt prevented the formation of these
structures on Matrigel-coated plates, implying that EC dif-
ferentiation into cord structures is also affected by this
natural alkaloid. Most strikingly, network-like structures
were not found when HUVEC was incubated with Pt and
just isolated cells were observed under the inverted micro-
scope, indicating that Pt can strongly disrupt tube forma-
tion (Figure 6a and 6b). Given the strong dependence of
cancer in angiogenesis, our findings led us to propose that
Pt can inhibit tumor growth through the suppression of
blood vessel development, being a potential anti-tumor
agent.
Vascular endothelial growth factor (VEGF) appears to play
a pivotal role in the angiogenic process, being involved in
a variety of normal and pathological circumstances
[2,22,23]. Accordingly, VEGF induces vascular permeabil-
ity, EC proliferation, migration and assembly into capil-
lary structures. Given the fact that Pt abrogates all these
Effect of Pt in HUVEC proliferation evaluated by BrdU assay Figure 3
Effect of Pt in HUVEC proliferation evaluated by 
BrdU assay. Incubation with 8 μM Pt resulted in a very sig-
nificant decrease in the percentage of proliferating cells. Bars 
represent the percentage of proliferating cells evaluated by 
the ratio of BrdU stained cells in 1000 hematoxylin stained 
nuclei. Assays were repeated five times and performed in 
triplicate. Statistical differences between groups were evalu-
ated by one-way analysis of variance (ANOVA test) followed 
by the Dunnet test. *p < 0.01 vs Control.BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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Effect of Pt in HUVEC apoptosis evaluated by TUNEL assay Figure 4
Effect of Pt in HUVEC apoptosis evaluated by TUNEL assay. a) The percentage of apoptotic cells was evaluated by the 
ratio between TUNEL-stained cells and DAPI-stained nuclei in every culture. Increased percentage of apoptotic cells was 
observed after incubation with 8 μM Pt. Results are expressed as percentage of control cells. Bars represent mean ± SD. 
Assays were repeated five times and performed in triplicate. Statistical differences between groups were evaluated by one-way 
analysis of variance (ANOVA test) followed by the Dunnet test. *p < 0.01 vs. Control. b) Apoptotic HUVEC representative 
photomicrographs stained with DAPI and detected by TUNEL assay after Pt treatment. Incubation with 8 μM Pt resulted in 
increased apoptosis determined as the percentage of positive cells per 1000 DAPI-stained nuclei. Glass coverslips were visual-
ized under a fluorescence microscope (Nikon Eclipse 50i) at a magnification of 200×.BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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processes in the current study, the anti-angiogenic action
of this alkaloid might be due to the inhibition of VEGF
signaling. Nevertheless, several other growth factors and
signaling pathways play a role in angiogenesis. Similar to
Pt, sinomenine (Sn), an alkaloid extracted from the Chi-
nese medicinal plant Sinomenium acutum and used in
rheumatoid arthritis treatment over 2000 years, also dis-
rupts tube formation on Matrigel. Since tube formation of
EC on the Matrigel depends on migration and morpho-
logical differentiation, mimmicking angiogenesis, Kok et
al. [45] proposed that Sn inhibited basic fibroblast growth
factor (bFGF)-induced angiogenesis. These authors fur-
ther hypothesized that tube formation is highly depend-
ent on cell-cell adhesion, implying a putative role for
adhesion molecules such as ICAM-1 or E-selectin modu-
lated by Sn in HUVEC.
These findings are in agreement with other studies in the
literature, explaining the large effects of natural products
in angiogenesis. A variety of herbs that are traditionally
used for anticancer treatment also exhibit antiangiogenic
activity through multiple interdependent processes
(effects on gene expression, signal processing and enzyme
activities), including Artemisia annua, Viscum album, Cur-
cuma longa (curcumin), Scutellaria baicalensis, resveratrol
and proanthocyanidin (grape seed extract), Magnolia offic-
inalis, Camellia sinensis (green tea), Ginkgo biloba, querce-
tin, Poria cocos, Zingiber officinalis (ginger), Panax ginseng,
Rabdosia rubescens and Chinese destagnation herbs. A
potential advantage of phytochemicals and other com-
pounds derived from natural health products is that they
may act through multiple cell-signalling pathways and
reduce the development of cancer cell resistance [46].
Although the studies showed the regulation of multiple
signalling pathways by natural products, the evaluation of
possible mechanisms by which Pt act were still not well
understood.
Finally, we decided to explore whether Pt could block the
transcription factor NFκB, which generally enhances cell
proliferation and survival by targeting multiple sites of the
pathway. NFκB plays an important role in carcinogenesis,
as well as in the regulation of immune and inflammatory
responses, inducing the expression of diverse target genes
that promote cell proliferation, regulate apoptosis, facili-
tate angiogenesis and stimulate invasion and metastasis.
In addition, many cancer cells show aberrant or constitu-
tive NFκB activation which mediates resistance to chemo-
therapy and radiotherapy [47]. Therefore, given the
critical role of NFκB in the pathogenesis of cancer, specific
inhibitors against this factor would be useful in cancer
therapy. Agents that prevent cancer or inflammation have
been found to suppress NFκB activation. Numerous
reports indicate that ancient plants and their components
are potent as NFκB inibitors [48].
In the present research, Pt inhibited endothelial NFκB
activity (Figure 7). NFκB was previously shown to be
down-regulated by various chemopreventive phytochem-
icals [49,50]. Curcumin is a phytochemical that possesses
anti-angiogenic properties. It decreases migration and
invasion of EC and down-regulates NFκB and inhibits IκB
kinase, thereby suppressing proliferation and inducing
apoptosis [51]. According to Mohan et al. [52], NFκB spe-
cific inhibitors as parthenolide, inhibit EC proliferation as
well as NFκB DNA binding, exerting anti-endothelial cell
sprouting activity. Accordingly, and although further stud-
ies are required, the current results suggests that inactiva-
tion of NFκB by the alkaloid is probably one of the
mechanisms involved in the observed anti-angiogenic
effects on HUVEC.
Recently, it has been reported that many natural products
can act as angiogenesis inhibitors. To our knowledge, this
was the first report concerning the effects of Pt in angio-
genesis using HUVEC. Mojzis et al. [53] propose that ang-
iogenesis inhibitors are likely to change the face of
medicine in the next decade and particularly the chemo-
preventive agents that act on the highly specialized biol-
ogy of EC during neovascularization deserve special
attention.
Conclusion
Taken together, representing the sequential events in the
angiogenic process, Pt treatment showed strong anti-ang-
iogenic effects possibly through the inhibition of EC pro-
Effect of Pt in HUVEC migration capacity evaluated by double  chamber assay Figure 5
Effect of Pt in HUVEC migration capacity evaluated 
by double chamber assay. Incubation with 8 μM Pt 
resulted in decreased cell invasion. Bars represent the per-
centage of invading cells relative to the initial amount of cells 
cultured. Results are expressed as percentage of control 
cells. Assays were repeated five times and performed in trip-
licate. Statistical differences between groups were evaluated 
by one-way analysis of variance (ANOVA test) followed by 
the Dunnet test. *p < 0.01 vs. Control.BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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liferation, invasion and assembly into capillary-like
structures together with apoptosis induction. Our find-
ings also identify the mode of action of this natural prod-
uct through the inhibition of NFκB. Despite the fact that
cytotoxic effects were not addressed in the current study
for 8 μM concentration of Pt, these results demonstrate
that Pt might be a novel inhibitor of angiogenesis, sug-
gesting that it may be important in the development of
pharmaceutical drugs or providing model molecules for
the discovery of potential new agents useful in angiogen-
esis dependent diseases, especially tumor treatment or
prevention. Nevertheless, in vivo studies are mandatory in
order to support these findings.
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Capillary-like structures in HUVEC cultures and semiquantification of the tube formation index Figure 6
Capillary-like structures in HUVEC cultures and semiquantification of the tube formation index. a) Photomicro-
graphs of capillary-like structures assembly in HUVEC cultures after treatment with Pt. In contrast to control cells, incubation 
with 8 μM Pt resulted in absence of ramifications with undifferentiated cells. Photomicrographs are representative of the whole 
cultures. Every culture was established in triplicate and visualized under an inverted microscope (×400 magnification). b) Semi-
quantification of the tube formation index in HUVEC after incubation with 8 μM Pt. There is a drastic reduction in the number 
of capillary-like structures formed upon incubation with this compound. Bars correspond to the percentage of the number of 
tubule-like structures comparatively to control. Statistical differences between groups were evaluated by one-way analysis of 
variance (ANOVA test) followed by the Dunnet test (mean ± SD; *p < 0.01 vs. Control).BMC Complementary and Alternative Medicine 2009, 9:15 http://www.biomedcentral.com/1472-6882/9/15
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